Vestal Point Capital’s Belite Bio BLTE Stock Holding History

Vestal Point Capital’s Portfolio BLTE Stock Details BLTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-312,500	Closed	-$23.1M	–	83
2025 Q3	$23.1M	Buy	+312,500	New	+$20.5M	1.04%	36

Other funds holding BLTE

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vestal Point Capital's BLTE Position: Q4 2025 in Review

Vestal Point Capital sold out of Belite Bio (BLTE) in Q4 2025, closing a stake of 312,500 shares — an estimated $23.1M sold.

Vestal Point Capital first reported a position in BLTE in Q3 2025 and held it in 1 quarter. The position peaked at $23.1M in Q3 2025. 69 funds tracked by Wall St. Rank hold BLTE as of Q4 2025.

Vestal Point Capital reported no remaining Belite Bio position as of Q4 2025 after selling out during the quarter.
Vestal Point Capital sold 312,500 Belite Bio shares in Q4 2025, an estimated $23.1M.
Vestal Point Capital first reported a position in Belite Bio in Q3 2025 and held it in 1 quarter.
Vestal Point Capital's Belite Bio position peaked at $23.1M in Q3 2025.
69 funds tracked by Wall St. Rank held Belite Bio as of Q4 2025.

Based on Vestal Point Capital's 13F filing for Q4 2025, filed 17 Feb 2026.